Relay Therapeutics director option: 207,931 shares at $6.86

Relay Therapeutics (RLAY) reported an insider equity award.

Accepted by SEC EDGAR 11/06/2025 - 04:37 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Relay Therapeutics (RLAY) reported an insider equity award. A company director disclosed a stock option grant to buy 207,931 shares at an exercise price of $6.86 per share on November 4, 2025.

The option expires on November 3, 2035 and vests in 36 equal monthly installments after November 4, 2025, contingent on continued service. The filing indicates direct ownership of the derivative security.

Insider Trade Summary

Grant/Award: 207,931 shares

Grant/Award 1 txn

Insider COATS LONNEL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	207,931	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 207,931 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments after November 4, 2025, subject to the reporting person's continued service with the Issuer through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RLAY disclose on Form 4?

A director reported a stock option grant for 207,931 shares at an exercise price of $6.86.

When was the RLAY stock option granted?

The transaction date was November 4, 2025.

What is the vesting schedule for the RLAY option grant?

It vests in 36 equal monthly installments after November 4, 2025, subject to continued service.

When does the RLAY option expire?

The option expires on November 3, 2035.

What is the ownership form reported for this RLAY option?

The filing lists Direct (D) ownership of the derivative security.

What role does the reporting person have at RLAY?

The reporting person is a Director of Relay Therapeutics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COATS LONNEL

(Last) (First) (Middle)

C/O RELAY THERAPEUTICS, INC.

60 HAMPSHIRE STREET

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Relay Therapeutics, Inc. [ RLAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.86	11/04/2025		A		207,931		(1)	11/03/2035	Common Stock	207,931	$0	207,931	D

Explanation of Responses:

1. The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments after November 4, 2025, subject to the reporting person's continued service with the Issuer through each vesting date.

	/s/ Soo-Yeun Lim, as Attorney-in-Fact	11/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.